Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more

Client Associate

Charles Muriuki2024-12-29T00:04:53+00:00November 28, 2024|

This listing has expired.